The event is one of the foremost conferences for researchers globally to present their latest findings in the field of gastroenterology. Results from Dose Escalation in RESOLVE, an Ongoing Phase 1b/2a ...
YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the ...